The role of Peroxisome Proliferator-Activated Receptor-γ in breast cancer

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1025-1044

  Kotta Loizou, Ioly ^a,c   Giaginis, Constantinos ^b   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF THE AEGEAN   (Greece)

^c HELLENIC PASTEUR INSTITUTE   (Greece)

Author keywords

(PPAR and gamma; ); 15 deoxy 12,14 prostaglandin J2 (15d PGJ2); Anti cancer agents; Apoptosis; Breast cancer; Cell cycle arrest; Differentiation; Estrogen Receptors (ERs); Fatty acids; Growth inhibition; Ligands; Methylene substituted diindolylmetyhanes (CDIMs); Oncogenesis; Peroxisome Proliferator Activated Receptor and gamma; Prognostic value; Retinoid X Receptor (RXR); Statins; Thiazolidinediones (TZDs)

Indexed keywords

2 [1 CARBOXY 2 [4 [2 (5 METHYL 2 PHENYL 4 OXAZOLYL) ETHOXY] PHENYL] ETHYLAMINO] BENZOIC ACID METHYL ESTER; BARDOXOLONE; BETA CAROTENE; CCAAT ENHANCER BINDING PROTEIN; CIGLITAZONE; DOCOSAHEXAENOIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; ETALOCIB; FATTY ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INDOMETACIN; LINOLEIC ACID; LINOLENIC ACID; MATRIX METALLOPROTEINASE; MYC PROTEIN; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHTHALIC ACID; PIOGLITAZONE; RETINOID X RECEPTOR; ROSIGLITAZONE; S PHASE KINASE ASSOCIATED PROTEIN 2; STEARIDONIC ACID; THYMOQUINONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZINC FINGER PROTEIN;

ARTICLE; BREAST CANCER; DRUG TARGETING; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PPAR GAMMA;

EID: 84872246916     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529664     Document Type: Article

References (132)

1. Chawla, A.; Repa, J.J.; Evans, R.M.; Mangelsdorf, D.J. Nuclear receptors and lipid physiology: opening the X-files. Science, 2001, 294, (5548), 1866-1870.
2. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20, (5), 649-688.
3. Berger, J.; Moller, D.E. The mechanisms of action of PPARs. Annu. Rev. Med., 2002, 53, 409-435.
4. Fajas, L.; Auboeuf, D.; Raspe, E.; Schoonjans, K.; Lefebvre, A.M.; Saladin, R.; Najib, J.; Laville, M.; Fruchart, J.C.; Deeb, S.; Vidal-Puig, A.; Flier, J.; Briggs, M.R.; Staels, B.; Vidal, H.; Auwerx, J. The organization, promoter analysis, and expression of the human PPARgamma gene. J. Biol. Chem., 1997, 272, (30), 18779-18789.
5. Kliewer, S.A.; Forman, B.M.; Blumberg, B.; Ong, E.S.; Borgmeyer, U.; Mangelsdorf, D.J.; Umesono, K.; Evans, R.M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc. Natl. Acad. Sci. U.S.A., 1994, 91, (15), 7355-7359.
6. Braissant, O.; Foufelle, F.; Scotto, C.; Dauca, M.; Wahli, W. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology, 1996, 137, (1), 354-366.
7. Jain, S.; Pulikuri, S.; Zhu, Y.; Qi, C.; Kanwar, Y.S.; Yeldandi, A.V.; Rao, M.S.; Reddy, J.K. Differential expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) and its coactivators steroid receptor coactivator-1 and PPARbinding protein PBP in the brown fat, urinary bladder, colon, and breast of the mouse. Am. J. Pathol., 1998, 153, (2), 349-354.
8. Chawla, A.; Schwarz, E.J.; Dimaculangan, D.D.; Lazar, M.A. Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 1994, 135, (2), 798-800.
9. Han, S.; Roman, J. Peroxisome proliferator-activated receptor gamma: a novel target for cancer therapeutics? Anticancer Drugs, 2007, 18, (3), 237-244.
10. Gearing, K.L.; Gottlicher, M.; Teboul, M.; Widmark, E.; Gustafsson, J.A. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc. Natl. Acad. Sci. USA, 1993, 90, (4), 1440-144.
11. Feige, J.N.; Gelman, L.; Michalik, L.; Desvergne, B.; Wahli, W. From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog. Lipid Res., 2006, 45, (2), 120-159.
12. Jarrar, M.H.; Baranova, A. PPARgamma activation by thiazolidinediones (TZDs) may modulate breast carcinoma outcome: the importance of interplay with TGFbeta signalling. J. Cell Mol. Med., 2007, 11, (1), 71-87.
13. Oberkofler, H.; Esterbauer, H.; Linnemayr, V.; Strosberg, A.D.; Krempler, F.; Patsch, W. Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity. J. Biol. Chem., 2002, 277, (19), 16750-16757.
14. Leader, J.E.; Wang, C.; Fu, M.; Pestell, R.G. Epigenetic regulation of nuclear steroid receptors. Biochem. Pharmacol., 2006, 72, (11), 1589-1596.
15. Willson, T.M.; Lambert, M.H.; Kliewer, S.A. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu. Rev. Biochem., 2001, 70, 341-367.
16. Qi, C.; Zhu, Y.; Reddy, J.K. Peroxisome proliferator-activated receptors, coactivators, and downstream targets. Cell Biochem. Biophys., 2000, 32 Spring, 187-204.
17. Tolon, R.M.; Castillo, A.I.; Aranda, A. Activation of the prolactin gene by peroxisome proliferator-activated receptor-alpha appears to be DNA binding-independent. J. Biol. Chem., 1998, 273, (41), 26652-26661.
18. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998, 391, (6662), 79-82.
19. Feinstein, D.L.; Spagnolo, A.; Akar, C.; Weinberg, G.; Murphy, P.; Gavrilyuk, V.; Dello Russo, C. Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol., 2005, 70, (2), 177-188.
20. Willson, T.M.; Brown, P.J.; Sternbach, D.D.; Henke, B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem., 2000, 43, (4), 527-550.
21. Schopfer, F.J.; Lin, Y.; Baker, P.R.; Cui, T.; Garcia-Barrio, M.; Zhang, J.; Chen, K.; Chen, Y.E.; Freeman, B.A. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc. Natl. Acad. Sci. USA, 2005, 102, (7), 2340-2345.
22. Lehmann, J.M.; Moore, L.B.; Smith-Oliver, T.A.; Wilkison, W.O.; Willson, T.M.; Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem., 1995, 270, (22), 12953-12956.
23. Teresi, R.E.; Shaiu, C.W.; Chen, C.S.; Chatterjee, V.K.; Waite, K.A.; Eng, C. Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. Int. J. Cancer, 2006, 118, (10), 2390-2398.
24. Teresi, R.E.; Planchon, S.M.; Waite, K.A.; Eng, C. Regulation of the PTEN promoter by statins and SREBP. Hum. Mol. Genet., 2008, 17(7), 919-928.
25. Qin, C.; Morrow, D.; Stewart, J.; Spencer, K.; Porter, W.; Smith, R., 3rd; Phillips, T.; Abdelrahim, M.; Samudio, I.; Safe, S. A new class of peroxisome proliferator-activated receptor gamma (PPARgamma) agonists that inhibit growth of breast cancer cells: 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl)methanes. Mol. Cancer Ther., 2004, 3, (3), 247-260.
26. Su, Y.; Vanderlaag, K.; Ireland, C.; Ortiz, J.; Grage, H.; Safe, S.; Frankel, A.E. 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice. Breast Cancer Res., 2007, 9, (4), R56.
27. Vanderlaag, K.; Su, Y.; Frankel, A.E.; Grage, H.; Smith, R., 3rd; Khan, S.; Safe, S. 1,1-Bis(3'-indolyl)-1-(p-substituted phenyl) methanes inhibit proliferation of estrogen receptor-negative breast cancer cells by activation of multiple pathways. Breast Cancer Res. Treat., 2008, 109, (2), 273-283.
28. Venkata, N.G.; Robinson, J.A.; Cabot, P.J.; Davis, B.; Monteith, G.R.; Roberts-Thomson, S.J. Mono(2-ethylhexyl)phthalate and mono-n-butyl phthalate activation of peroxisome proliferator activated-receptors alpha and gamma in breast. Toxicol. Lett., 2006, 163, (3), 224-234.
29. Mora, F.D.; Jones, D.K.; Desai, P.V.; Patny, A.; Avery, M.A.; Feller, D.R.; Smillie, T.; Zhou, Y.D.; Nagle, D.G. Bioassay for the identification of natural product-based activators of peroxisome proliferator-activated receptor-gamma (PPARgamma): the marine sponge metabolite psammaplin A activates PPARgamma and induces apoptosis in human breast tumor cells. J. Nat. Prod., 2006, 69(4), 547-552.
30. Mathews, W.B.; Foss, C.A.; Stoermer, D.; Ravert, H.T.; Dannals, R.F.; Henke, B.R.; Pomper, M.G. Synthesis and biodistribution of (11)C-GW7845, a positron-emitting agonist for peroxisome proliferator-activated receptor-{gamma}. J. Nucl. Med., 2005, 46(10), 1719-1726.
31. Lee, H.; Finck, B.N.; Jones, L.A.; Welch, M.J.; Mach, R.H. Synthesis and evaluation of a bromine-76-labeled PPARgamma antagonist 2-bromo-5-nitro-N-phenylbenzamide. Nucl. Med. Biol., 2006, 33, (7), 847-54.
32. Kim, E.H.; Na, H.K.; Surh, Y.J. Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. Ann. N. Y. Acad. Sci., 2006, 1090, 375-384.
33. Migita, H.; Morser, J. 15-deoxy-Delta12,14-prostaglandin J2 (15d-PGJ2) signals through retinoic acid receptor-related orphan receptor-alpha but not peroxisome proliferator-activated receptorgamma in human vascular endothelial cells: the effect of 15d-PGJ2 on tumor necrosis factor-alpha-induced gene expression. Arterioscler. Thromb. Vasc. Biol., 2005, 25(4), 710-716.
34. Kim, H.J.; Kim, J.Y.; Meng, Z.; Wang, L.H.; Liu, F.; Conrads, T.P.; Burke, T.R.; Veenstra, T.D.; Farrar, W.L. 15-deoxy-Delta12,14-prostaglandin J2 inhibits transcriptional activity of estrogen receptor-alpha via covalent modification of DNA-binding domain. Cancer Res., 2007, 67(6), 2595-2602.
35. Wang, X.; Southard, R.C.; Kilgore, M.W. The increased expression of peroxisome proliferator-activated receptor-gamma1 in human breast cancer is mediated by selective promoter usage. Cancer Res., 2004, 64(16), 5592-5596.
36. Gery, S.; Tanosaki, S.; Bose, S.; Bose, N.; Vadgama, J.; Koeffler, H.P. Down-regulation and growth inhibitory role of C/EBPalpha in breast cancer. Clin. Cancer Res., 2005, 11, (9), 3184-3190.
37. Yang, Z.; Bagheri-Yarmand, R.; Balasenthil, S.; Hortobagyi, G.; Sahin, A.A.; Barnes, C.J.; Kumar, R. HER2 regulation of peroxisome proliferator-activated receptor gamma (PPARgamma) expression and sensitivity of breast cancer cells to PPARgamma ligand therapy. Clin. Cancer Res., 2003, 9(8), 3198-3203.
38. Yu, H.N.; Lee, Y.R.; Noh, E.M.; Lee, K.S.; Kim, J.S.; Song, E.K.; Han, M.K.; Lee, Y.C.; Kwon, K.B.; Lee, S.J.; Youn, H.J.; Jung, S.H. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand. Cell Biol. Int., 2008, 32(8), 906-912.
39. Wang, X.; Southard, R.C.; Allred, C.D.; Talbert, D.R.; Wilson, M.E.; Kilgore, M.W. MAZ drives tumor-specific expression of PPAR gamma 1 in breast cancer cells. Breast Cancer Res. Treat., 2008, 111, (1), 103-11.
40. Suh, N.; Wang, Y.; Williams, C.R.; Risingsong, R.; Gilmer, T.; Willson, T.M.; Sporn, M.B. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. Cancer Res., 1999, 59(22), 5671-5673.
41. Mueller, E.; Sarraf, P.; Tontonoz, P.; Evans, R.M.; Martin, K.J.; Zhang, M.; Fletcher, C.; Singer, S.; Spiegelman, B.M. Terminal differentiation of human breast cancer through PPAR gamma. Mol. Cell, 1998, 1, (3), 465-470.
42. Yee, L.D.; Young, D.C.; Rosol, T.J.; Vanbuskirk, A.M.; Clinton, S.K. Dietary (n-3) polyunsaturated fatty acids inhibit HER-2/neuinduced breast cancer in mice independently of the PPARgamma ligand rosiglitazone. J. Nutr., 2005, 135(5), 983-988.
43. Kilgore, M.W.; Tate, P.L.; Rai, S.; Sengoku, E.; Price, T.M. MCF-7 and T47D human breast cancer cells contain a functional peroxisomal response. Mol. Cell Endocrinol., 1997, 129(2), 229-235.
44. Elstner, E.; Muller, C.; Koshizuka, K.; Williamson, E.A.; Park, D.; Asou, H.; Shintaku, P.; Said, J.W.; Heber, D.; Koeffler, H.P. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc. Natl. Acad. Sci. U.S.A., 1998, 95(15), 8806-8811.
45. Rashid-Kolvear, F.; Taboski, M.A.; Nguyen, J.; Wang, D.Y.; Harrington, L.A.; Done, S.J. Troglitazone suppresses telomerase activity independently of PPARgamma in estrogen-receptor negative breast cancer cells. BMC Cancer, 10, 390.
46. Jiang, W.G.; Redfern, A.; Bryce, R.P.; Mansel, R.E. Peroxisome proliferator activated receptor-gamma (PPAR-gamma) mediates the action of gamma linolenic acid in breast cancer cells. Prostaglandins Leukot. Essent. Fatty Acids, 2000, 62(2), 119-127.
47. Lekstrom-Himes, J.; Xanthopoulos, K.G. Biological role of the CCAAT/enhancer-binding protein family of transcription factors. J. Biol. Chem., 1998, 273(44), 28545-28548.
48. McKnight, S.L. McBindall--a better name for CCAAT/enhancer binding proteins? Cell, 2001, 107(3), 259-261.
49. Gigliotti, A.P.; DeWille, J.W. Lactation status influences expression of CCAAT/enhancer binding protein isoform mRNA in the mouse mammary gland. J. Cell Physiol., 1998, 174(2), 232-239.
50. Muss, H.B.; Thor, A.D.; Berry, D.A.; Kute, T.; Liu, E.T.; Koerner, F.; Cirrincione, C.T.; Budman, D.R.; Wood, W.C.; Barcos, M.; Henderson, I.C. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 1994, 330(18), 1260-1266.
51. Borg, A.; Baldetorp, B.; Ferno, M.; Killander, D.; Olsson, H.; Ryden, S.; Sigurdsson, H. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett., 1994, 81(2), 137-144.
52. Carraway, K.L., 3rd; Cantley, L.C. A neu acquaintance for erbB3 and erbB4: a role for receptor heterodimerization in growth signaling. Cell, 1994, 78(1), 5-8.
53. Kumar, R.; Mandal, M.; Vadlamudi, R. New insights into anti-HER-2 receptor monoclonal antibody research. Semin. Oncol., 2000, 27(6 Suppl 11), 84-91; discussion 92-100.
54. Kurokawa, H.; Lenferink, A.E.; Simpson, J.F.; Pisacane, P.I.; Sliwkowski, M.X.; Forbes, J.T.; Arteaga, C.L. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res., 2000, 60(20), 5887-5894.
55. Cuello, M.; Ettenberg, S.A.; Clark, A.S.; Keane, M.M.; Posner, R.H.; Nau, M.M.; Dennis, P.A.; Lipkowitz, S. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res., 2001, 61(12), 4892-900.
56. Baselga, J.; Pfister, D.; Cooper, M.R.; Cohen, R.; Burtness, B.; Bos, M.; D'Andrea, G.; Seidman, A.; Norton, L.; Gunnett, K.; Falcey, J.; Anderson, V.; Waksal, H.; Mendelsohn, J. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 2000, 18, (4), 904-914.
57. Mongroo, P.S.; Johnstone, C.N.; Naruszewicz, I.; Leung-Hagesteijn, C.; Sung, R.K.; Carnio, L.; Rustgi, A.K.; Hannigan, G.E. Beta-parvin inhibits integrin-linked kinase signaling and is downregulated in breast cancer. Oncogene, 2004, 23(55), 8959-8970.
58. Iankova, I.; Petersen, R.K.; Annicotte, J.S.; Chavey, C.; Hansen, J.B.; Kratchmarova, I.; Sarruf, D.; Benkirane, M.; Kristiansen, K.; Fajas, L. Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis. Mol. Endocrinol., 2006, 20(7), 1494-1505.
59. Marshall, N.F.; Price, D.H. Purification of P-TEFb, a transcription factor required for the transition into productive elongation. J Biol Chem., 1995, 270, (21), 12335-8.
60. Chinetti, G.; Lestavel, S.; Bocher, V.; Remaley, A.T.; Neve, B.; Torra, I.P.; Teissier, E.; Minnich, A.; Jaye, M.; Duverger, N.; Brewer, H.B.; Fruchart, J.C.; Clavey, V.; Staels, B. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med., 2001, 7(1), 53-8.
61. Moore, K.J.; Rosen, E.D.; Fitzgerald, M.L.; Randow, F.; Andersson, L.P.; Altshuler, D.; Milstone, D.S.; Mortensen, R.M.; Spiegelman, B.M.; Freeman, M.W. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med., 2001, 7,(1), 41-47.
62. Johnstone, C.N.; Mongroo, P.S.; Rich, A.S.; Schupp, M.; Bowser, M.J.; Delemos, A.S.; Tobias, J.W.; Liu, Y.; Hannigan, G.E.; Rustgi, A.K. Parvin-beta inhibits breast cancer tumorigenicity and promotes CDK9-mediated peroxisome proliferator-activated receptor gamma 1 phosphorylation. Mol. Cell Biol., 2008, 28(2), 687-704.
63. Riboli, E.; Norat, T. Epidemiologic evidence of the protective effect of fruit and vegetables on cancer risk. Am. J. Clin. Nutr., 2003, 78(3 Suppl), 559S-569S.
64. Gandini, S.; Merzenich, H.; Robertson, C.; Boyle, P. Meta-analysis of studies on breast cancer risk and diet: the role of fruit and vegetable consumption and the intake of associated micronutrients. Eur. J. Cancer, 2000, 36(5), 636-646.
65. Cui, Y.; Lu, Z.; Bai, L.; Shi, Z.; Zhao, W.E.; Zhao, B. beta-Carotene induces apoptosis and up-regulates peroxisome proliferator-activated receptor gamma expression and reactive oxygen species production in MCF-7 cancer cells. Eur. J. Cancer, 2007, 43(17), 2590-2601.
66. Love, R.R. Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J. Natl. Cancer Inst., 1999, 91(21), 1891-1892.
67. Evans, R.M. The steroid and thyroid hormone receptor superfamily. Science, 1988, 240(4854), 889-895.
68. Kuiper, G.G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 1996, 93(12), 5925-5930.
69. Couse, J.F.; Korach, K.S. Estrogen receptor null mice: what have we learned and where will they lead us? Endocr. Rev., 1999, 20, (3), 358-417.
70. Aronica, S.M.; Kraus, W.L.; Katzenellenbogen, B.S. Estrogen action via the cAMP signaling pathway: stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proc. Natl. Acad. Sci. USA, 1994, 91(18), 8517-8521.
71. Migliaccio, A.; Di Domenico, M.; Castoria, G.; de Falco, A.; Bontempo, P.; Nola, E.; Auricchio, F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. Embo J., 1996, 15(6), 1292-1300.
72. Eisen, A.; Weber, B.L. Recent advances in breast cancer biology. Curr. Opin. Oncol., 1998, 10(6), 486-491.
73. Nicholson, R.I.; McClelland, R.A.; Robertson, J.F.; Gee, J.M. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr. Relat. Cancer, 1999, 6(3), 373-387.
74. Jensen, E.V. Steroid hormone antagonists. Summary and future challenges. Ann. NY Acad. Sci., 1995, 761, 1-4.
75. Qi, C.; Zhu, Y.T.; Chang, J.; Yeldandi, A.V.; Rao, M.S.; Zhu, Y.J. Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2. Biochem. Biophys. Res. Commun., 2005, 328(2), 393-398.
76. Datta, S.R.; Brunet, A.; Greenberg, M.E. Cellular survival: a play in three Akts. Genes Dev., 1999, 13(22), 2905-2927.
77. Simoncini, T.; Hafezi-Moghadam, A.; Brazil, D.P.; Ley, K.; Chin, W.W.; Liao, J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature, 2000, 407, (6803), 538-541.
78. Keller, H.; Givel, F.; Perroud, M.; Wahli, W. Signaling cross-talk between peroxisome proliferator-activated receptor/retinoid X receptor and estrogen receptor through estrogen response elements. Mol. Endocrinol., 1995, 9(7), 794-804.
79. Min, G. Different modulation of ER-mediated transactivation by xenobiotic nuclear receptors depending on the estrogen response elements and estrogen target cell types. Ann. NY Acad. Sci., 2006, 1091, 244-257.
80. Bonofiglio, D.; Gabriele, S.; Aquila, S.; Catalano, S.; Gentile, M.; Middea, E.; Giordano, F.; Ando, S. Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clin. Cancer Res., 2005, 11(17), 6139-6147.
81. Wang, X.; Kilgore, M.W. Signal cross-talk between estrogen receptor alpha and beta and the peroxisome proliferator-activated receptor gamma1 in MDA-MB-231 and MCF-7 breast cancer cells. Mol. Cell Endocrinol., 2002, 194(1-2), 123-1233.
82. Patel, L.; Pass, I.; Coxon, P.; Downes, C.P.; Smith, S.A.; Macphee, C.H. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr. Biol., 2001, 11(10), 764-768.
83. Cantley, L.C.; Neel, B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci., U.S.A., 1999, 96(8), 4240-4245.
84. Nagasaki, K.; Maass, N.; Manabe, T.; Hanzawa, H.; Tsukada, T.; Kikuchi, K.; Yamaguchi, K. Identification of a novel gene, DAM1, amplified at chromosome 1p13.3-21 region in human breast cancer cell lines. Cancer Lett., 1999, 140(1-2), 219-226.
85. Crowe, D.L.; Chandraratna, R.A. A retinoid X receptor (RXR)-selective retinoid reveals that RXR-alpha is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands. Breast Cancer Res., 2004, 6(5), R546-R555.
86. Cui, Y.; Miyoshi, K.; Claudio, E.; Siebenlist, U.K.; Gonzalez, F.J.; Flaws, J.; Wagner, K.U.; Hennighausen, L. Loss of the peroxisome proliferation-activated receptor gamma (PPARgamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J. Biol. Chem., 2002, 277, (20), 17830-17835.
87. Saez, E.; Rosenfeld, J.; Livolsi, A.; Olson, P.; Lombardo, E.; Nelson, M.; Banayo, E.; Cardiff, R.D.; Izpisua-Belmonte, J.C.; Evans, R.M. PPAR gamma signaling exacerbates mammary gland tumor development. Genes Dev., 2004, 18(5), 528-540.
88. Gimble, J.M.; Pighetti, G.M.; Lerner, M.R.; Wu, X.; Lightfoot, S.A.; Brackett, D.J.; Darcy, K.; Hollingsworth, A.B. Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochem. Biophys. Res. Commun., 1998, 253(3), 813-817.
89. Ikezoe, T.; Miller, C.W.; Kawano, S.; Heaney, A.; Williamson, E.A.; Hisatake, J.; Green, E.; Hofmann, W.; Taguchi, H.; Koeffler, H.P. Mutational analysis of the peroxisome proliferator-activated receptor gamma gene in human malignancies. Cancer Res., 2001, 61(13), 5307-5310.
90. Nwankwo, J.O.; Robbins, M.E. Peroxisome proliferator-activated receptor-gamma expression in human malignant and normal brain, breast and prostate-derived cells. Prostaglandins Leukot. Essent. Fatty Acids, 2001, 64(4-5), 241-245.
91. Taipale, J.; Beachy, P.A. The Hedgehog and Wnt signalling pathways in cancer. Nature, 2001, 411(6835), 349-354.
92. Wang, C.; Pattabiraman, N.; Zhou, J.N.; Fu, M.; Sakamaki, T.; Albanese, C.; Li, Z.; Wu, K.; Hulit, J.; Neumeister, P.; Novikoff, P.M.; Brownlee, M.; Scherer, P.E.; Jones, J.G.; Whitney, K.D.; Donehower, L.A.; Harris, E.L.; Rohan, T.; Johns, D.C.; Pestell, R.G. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol. Cell Biol., 2003, 23(17), 6159-6173.
93. Meirhaeghe, A.; Amouyel, P. Impact of genetic variation of PPARgamma in humans. Mol. Genet. Metab., 2004, 83(1-2), 93-102.
94. Masugi, J.; Tamori, Y.; Mori, H.; Koike, T.; Kasuga, M. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem. Biophys. Res. Commun., 2000, 268(1), 178-182.
95. Vogel, U.; Christensen, J.; Nexo, B.A.; Wallin, H.; Friis, S.; Tjonneland, A. Peroxisome proliferator-activated [corrected] receptor-gamma2 [corrected] Pro12Ala, interaction with alcohol intake and NSAID use, in relation to risk of breast cancer in a prospective study of Danes. Carcinogenesis, 2007, 28(2), 427-434.
96. Harris, R.E.; Beebe-Donk, J.; Alshafie, G.A. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer, 2006, 6, 27.
97. Rahme, E.; Ghosn, J.; Dasgupta, K.; Rajan, R.; Hudson, M. Association between frequent use of nonsteroidal antiinflammatory drugs and breast cancer. BMC Cancer, 2005, 5, 159.
98. Gallicchio, L.; McSorley, M.A.; Newschaffer, C.J.; Huang, H.Y.; Thuita, L.W.; Hoffman, S.C.; Helzlsouer, K.J. Body mass, polymorphisms in obesity-related genes, and the risk of developing breast cancer among women with benign breast disease. Cancer Detect Prev., 2007, 31(2), 95-101.
99. Meng, J.; Ding, Y.; Shen, A.; Yan, M.; He, F.; Ji, H.; Zou, L.; Liu, Y.; Wang, Y.; Lu, X.; Wang, H. Overexpression of PPARgamma can down-regulate Skp2 expression in MDA-MB-231 breast tumor cells. Mol. Cell Biochem., 345(1-2), 171-180.
100. Egeblad, M.; Werb, Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer, 2002, 2,(3), 161-174.
101. Mylona, E.; Nomikos, A.; Magkou, C.; Kamberou, M.; Papassideri, I.; Keramopoulos, A.; Nakopoulou, L. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1-MMP) and MMP-9 according to their localization in invasive breast carcinoma. Histopathology, 2007, 50(3), 338-347.
102. Papadaki, I.; Mylona, E.; Giannopoulou, I.; Markaki, S.; Keramopoulos, A.; Nakopoulou, L. PPARgamma expression in breast cancer: clinical value and correlation with ERbeta. Histopathology, 2005, 46(1), 37-42.
103. van de Vijver, M.J. Biological variables and prognosis of DCIS. Breast, 2005, 14(6), 509-519.
104. Kulkarni, S.; Patil, D.B.; Diaz, L.K.; Wiley, E.L.; Morrow, M.; Khan, S.A. COX-2 and PPARgamma expression are potential markers of recurrence risk in mammary duct carcinoma in-situ. BMC Cancer, 2008, 8, 36.
105. Allred, C.D.; Kilgore, M.W. Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Mol. Cell Endocrinol., 2005, 235(1-2), 21-29.
106. Thompson, M.E.; Jensen, R.A.; Obermiller, P.S.; Page, D.L.; Holt, J.T. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat. Genet., 1995, 9(4), 444-450.
107. Wilson, C.A.; Ramos, L.; Villasenor, M.R.; Anders, K.H.; Press, M.F.; Clarke, K.; Karlan, B.; Chen, J.J.; Scully, R.; Livingston, D.; Zuch, R.H.; Kanter, M.H.; Cohen, S.; Calzone, F.J.; Slamon, D.J. Localization of human BRCA1 and its loss in highgrade, non-inherited breast carcinomas. Nat. Genet., 1999, 21(2), 236-240.
108. Pignatelli, M.; Cocca, C.; Santos, A.; Perez-Castillo, A. Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene, 2003, 22(35), 5446-5450.
109. Pignatelli, M.; Cortes-Canteli, M.; Lai, C.; Santos, A.; Perez-Castillo, A. The peroxisome proliferator-activated receptor gamma is an inhibitor of ErbBs activity in human breast cancer cells. J. Cell Sci., 2001, 114(Pt 22), 4117-4126.
110. Chbicheb, S.; Yao, X.; Rodeau, J.L.; Salamone, S.; Boisbrun, M.; Thiel, G.; Spohn, D.; Grillier-Vuissoz, I.; Chapleur, Y.; Flament, S.; Mazerbourg, S. EGR1 expression: A calcium and ERK1/2 mediated PPAR(gamma)-independent event involved in the antiproliferative effect of 15-deoxy-Delta12,14-prostaglandin J2 and thiazolidinediones in breast cancer cells. Biochem. Pharmacol. 81(9), 1087-1097.
111. Bocca, C.; Bozzo, F.; Francica, S.; Colombatto, S.; Miglietta, A. Involvement of PPAR gamma and E-cadherin/beta-catenin pathway in the antiproliferative effect of conjugated linoleic acid in MCF-7 cells. Int. J. Cancer, 2007, 121(2), 248-256.
112. Thoennes, S.R.; Tate, P.L.; Price, T.M.; Kilgore, M.W. Differential transcriptional activation of peroxisome proliferator-activated receptor gamma by omega-3 and omega-6 fatty acids in MCF-7 cells. Mol. Cell Endocrinol., 2000, 160(1-2), 67-73.
113. Horia, E.; Watkins, B.A. Comparison of stearidonic acid and alphalinolenic acid on PGE2 production and COX-2 protein levels in MDA-MB-231 breast cancer cell cultures. J. Nutr. Biochem., 2005, 16(3), 184-192.
114. Jiang, W.G.; Hiscox, S.; Horrobin, D.F.; Bryce, R.P.; Mansel, R.E. Gamma linolenic acid regulates expression of maspin and the motility of cancer cells. Biochem. Biophys. Res. Commun., 1997, 237, (3), 639-44.
115. Sun, H.; Berquin, I.M.; Edwards, I.J. Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res., 2005, 65(10), 4442-4447.
116. Carter, J.C.; Church, F.C. Peroxisome Proliferator-Activated Receptor-gamma Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System. J. Oncol., 2011, 594258.
117. Zheng, Z.H.; Yang, Y.; Lu, X.H.; Zhang, H.; Shui, X.X.; Liu, C.; He, X.B.; Jiang, Q.; Zhao, B.H.; Si, S.Y. Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARgamma. Eur. J. Pharmacol., 658, (1), 1-8.
118. Woo, C.C.; Loo, S.Y.; Gee, V.; Yap, C.W.; Sethi, G.; Kumar, A.P.; Tan, K.H. Anticancer activity of thymoquinone in breast cancer cells: possible involvement of PPAR-gamma pathway. Biochem. Pharmacol., 82(5), 464-475.
119. Turturro, F.; Friday, E.; Fowler, R.; Surie, D.; Welbourne, T. Troglitazone acts on cellular pH and DNA synthesis through a peroxisome proliferator-activated receptor gamma-independent mechanism in breast cancer-derived cell lines. Clin. Cancer Res., 2004, 10(20), 7022-7030.
120. Murad, H.; Collet, P.; Huin-Schohn, C.; Al-Makdissy, N.; Kerjan, G.; Chedotal, A.; Donner, M.; Devignes, M.D.; Becuwe, P.; Schohn, H.; Domenjoud, L.; Dauca, M. Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells. Int. J. Oncol., 2006, 28(4), 977-984.
121. Kim, K.Y.; Kim, S.S.; Cheon, H.G. Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochem. Pharmacol., 2006, 72(5), 530-540.
122. Seargent, J.M.; Yates, E.A.; Gill, J.H. GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. Br. J. Pharmacol., 2004, 143(8), 933-937.
123. Bonofiglio, D.; Aquila, S.; Catalano, S.; Gabriele, S.; Belmonte, M.; Middea, E.; Qi, H.; Morelli, C.; Gentile, M.; Maggiolini, M.; Ando, S. Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Mol. Endocrinol., 2006, 20(12), 3083-3092.
124. Nunez, N.P.; Liu, H.; Meadows, G.G. PPAR-gamma ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells. Cancer Lett., 2006, 236(1), 133-141.
125. Fenner, M.H.; Elstner, E. Peroxisome proliferator-activated receptor-gamma ligands for the treatment of breast cancer. Expert Opin. Investig. Drugs, 2005, 14(6), 557-568.
126. Konopleva, M.; Zhang, W.; Shi, Y.X.; McQueen, T.; Tsao, T.; Abdelrahim, M.; Munsell, M.F.; Johansen, M.; Yu, D.; Madden, T.; Safe, S.H.; Hung, M.C.; Andreeff, M. Synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest in HER2-overexpressing breast cancer cells. Mol. Cancer Ther., 2006, 5(2), 317-328.
127. Budman, D.R.; Calabro, A.; Kreis, W. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. Anticancer Drugs, 1998, 9(8), 697-702.
128. Burstein, H.J.; Demetri, G.D.; Mueller, E.; Sarraf, P.; Spiegelman, B.M.; Winer, E.P. Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res. Treat, 2003, 79(3), 391-397.
129. Yee, L.D.; Williams, N.; Wen, P.; Young, D.C.; Lester, J.; Johnson, M.V.; Farrar, W.B.; Walker, M.J.; Povoski, S.P.; Suster, S.; Eng, C. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin. Cancer Res., 2007, 13(1), 246-252.
130. Youssef, J.; Badr, M. Peroxisome proliferator-activated receptors and cancer: challenges and opportunities. Br. J. Pharmacol., 164(1), 68-82.
131. Catalano, S.; Mauro, L.; Bonofiglio, D.; Pellegrino, M.; Qi, H.; Rizza, P.; Vizza, D.; Bossi, G.; Ando, S. In vivo and in vitro evidence that PPARgamma ligands are antagonists of leptin signaling in breast cancer. Am. J. Pathol., 179(2), 1030-1040.
132. Jiang, Y.; Huang, Y.; Cheng, C.; Lu, W.; Zhang, Y.; Liu, X.; Zou, L.; Ben, Q.; Shen, A. Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by PPARgamma up-expression in MDA-MB-231 cells. Exp. Mol. Pathol., 91(3), 768-774.